HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

CNTO 148

HCID 178709390
New reaction
Print

Completing data — refresh the page later to see the latest

Names & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
No structure available

Names & identifiers

Preferred name
CNTO 148
English name
CNTO 148
Molecular weight
0

Names & synonyms

GolimumabSimponiCNTO 148Golimumab CRSGolimumab BRPResearch Grade GolimumabMK-8259|||SCH 900259|||CNTO-148Research Grade Golimumab (DHB94404)

Database identifiers

CAS
476181-74-5

Properties

Physicochemical properties

storage temp.
-20 °C · Store at -20°C
form
Liquid
color
Colorless to light yellow
FDA UNII
91 X1KLU43E · 91X1KLU43E
NCI Drug Dictionary
golimumab
ATC code
4 AB06 · L04AB06
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
334 · H334
Precautionary statements
261 · P261-P285-P304+P341-P342+P311-P501
Hazardous Substances Data
476181 · 476181-74-5(Hazardous Substances Data)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Danger
Symbol(GHS)
GHS08
Hazard statements
H334
Precautionary statements
P261-P285-P304+P341-P342+P311-P501
Hazardous Substances Data
476181-74-5(Hazardous Substances Data)

Chemistry & industry

Applications · 2 items

DescriptionThe proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful strategy in the intervention of a range of immunoinflammatory disorders. Biologics have risen to the forefront of TNF-α blockade with infliximab, a chimeric monoclonal antibody (mAb), and etanercept, a fusion protein comprised of the ligand-binding segment of the soluble TNF receptor, reaching the market in the late 1990s for the initial indication of RA. Since then, their use has expanded to other diseases of inflammatory etiology, and two additional TNF-α inhibitors have joined the competition. Golimumab, a human anti-TNF-α mAb that binds to both soluble and transmembrane forms of TNF-a, is the first once-monthly subcutaneous agent to enter the market and is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS. .

UsesTreatment of allergic asthma.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes